News

Jagsonpal Pharmaceuticals has allotted 1,93,000 equity shares under ESOP on 27 April 2026.

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 27 April 2026, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.

Net profit of Jagsonpal Pharmaceuticals rose 33.13% to Rs 8.76 crore in the quarter ended March 2026 as against Rs 6.58 crore during the previous quarter ended March 2025. Sales rose 9.63% to Rs 64.20 crore in the quarter ended March 2026 as against Rs 58.56 crore during the previous quarter ended March 2025.For the full year,net profit declined 22.18% to Rs 43.08 crore in the year ended March 2026 as against Rs 55.36 crore during the previous year ended March 2025. Sales rose 6.89% to Rs 287.23 crore in the year ended March 2026 as against Rs 268.72 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales64.2058.56 10 287.23268.72 7 OPM %17.3714.89 -20.2219.00 - PBDT14.0711.23 25 69.0458.30 18 PBT11.758.92 32 59.6050.17 19 NP8.766.58 33 43.0855.36 -22 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 April 2026.

Jagsonpal Pharmaceuticals has allotted 1,76,900 equity shares under ESOP on 13 April 2026. With this allotment, the paid up equity share capital has increased to Rs. 13,42,78,300 (constituting of 6,71,39,150 equity shares of Rs. 2/- each).